Brief: Intellia Therapeutics Q2 Net Income USD -101.255 Million

INTELLIA THERAPEUTICS

07/08/2025 12:30

Overview

Intellia Q2 collaboration revenue rises to $14.2 mln from $6.9 mln yr ago

Net loss narrows to $101.3 mln from $147.0 mln yr ago

Co progressing ahead of schedule in Phase 3 trials for ATTR amyloidosis and HAE

Outlook

Company expects cash reserves to fund operations into H1 2027

Result Drivers

COLLABORATION REVENUE - Increase due to cost reimbursements from Regeneron Pharmaceuticals collaboration

  COST DECLINE - R&D and G&A expenses dwcline year over year due to lower stock-based compensation, among other reasons

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
$14.24 mln
Q2 Net Income
-$101.26 mln
Q2 Basic EPS
-$0.98
Q2 Operating Expenses
$124.24 mln
Q2 Operating Income
-$110 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Intellia Therapeutics Inc is $30.00, about 62.1% above its August 6 closing price of $11.37

Press Release: ID:nGNX4YW9MW

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)